Clinical Trials

    Showing 1 - 7 of 7 Digestive System Diseases

    5-Fluorouracil/?Leucovorin (5FU/?LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.... Read more >

    A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes

    Status: Enrolling

    Investigator: Abhishek Kansara

    Study Coordinator:

    Phone:

    This research study is designed to evaluate the safety and effectiveness of the ReCET™ device for improving glycemic (blood sugar) control in individuals with T2D. This study plans to enroll a minimum of 264 and a maximum of 350 participants from ... Read more >

    A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >

    Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >

    DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (MUIR-3 STUDY)

    Status: Open Not Enrolling

    Investigator: Abhishek Kansara

    Study Coordinator: Jhonny Aguilera

    Phone: 281.515.5710

    This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for eligib... Read more >

    DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)

    Status: Open Not Enrolling

    Investigator: Abhishek Kansara

    Study Coordinator:

    Phone:

    This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for eligib... Read more >

    Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, an... Read more >